IJC Heart and Vasculature最新文献

{"title":"High-intensity interval training improves mitochondrial function and attenuates cardiomyocytes damage in ischemia-reperfusion","authors":"Zhan Wei ,&nbsp;Mujahid Ahmad ,&nbsp;Rongzhi Chen ,&nbsp;Sana Fatima ,&nbsp;Shahab Shah","doi":"10.1016/j.ijcha.2025.101756","DOIUrl":"10.1016/j.ijcha.2025.101756","url":null,"abstract":"<div><div>Ischemic heart disease remains a leading cause of global mortality and morbidity, underscoring the urgent need for effective therapies particularly for patients recovering from ischemic cardiac events. High-intensity interval training (HIIT) has emerged as a promising non-pharmacological intervention with substantial cardioprotective potential. Both clinical studies and animal models demonstrate that HIIT attenuates cardiac damage induced by ischemia–reperfusion injury. However, the precise cellular and molecular mechanisms underlying these benefits remain incompletely elucidated. Mitochondria play a pivotal yet dual role in ischemia–reperfusion injury, serving as central regulators of both cell survival and death pathways. Although HIIT is recognized to modulate mitochondrial function, its specific impact on cardiac susceptibility to ischemic injury requires further clarification. This review synthesizes current evidence on the beneficial effects of HIIT on cardiac mitochondrial function, with a focus on the mechanisms through which it confers cardioprotection. We examine how HIIT may enhance mitochondrial resilience by activating critical signaling pathways that mitigate ischemia–reperfusion injury. Despite significant advances, key knowledge gaps persist. This review emphasizes the necessity of further research to fully unravel HIIT’s cardioprotective potential and its role in promoting mitochondrial adaptation under ischemic stress.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101756"},"PeriodicalIF":2.5,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy","authors":"Chongyang Yan ,&nbsp;Yuhang Cao ,&nbsp;Shubo Song ,&nbsp;Ziyang Wang ,&nbsp;Xiaobo Liu ,&nbsp;Taibing Fan","doi":"10.1016/j.ijcha.2025.101742","DOIUrl":"10.1016/j.ijcha.2025.101742","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101742"},"PeriodicalIF":2.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of infarct characteristics and left ventricular function on serial CMR in STEMI patients treated with post-PCI sonothrombolysis: post-hoc analysis of two randomized controlled trials","authors":"Soufiane El Kadi ,&nbsp;Shouqiang Li ,&nbsp;Chad Hovseth ,&nbsp;Luuk H.G.A. Hopman ,&nbsp;Mariëlle C. van de Veerdonk ,&nbsp;Niels J.W. Verouden ,&nbsp;Feng Xie ,&nbsp;Albert C. van Rossum ,&nbsp;Otto Kamp ,&nbsp;Thomas R. Porter","doi":"10.1016/j.ijcha.2025.101757","DOIUrl":"10.1016/j.ijcha.2025.101757","url":null,"abstract":"<div><h3>Background</h3><div>Several randomized clinical trials have studied sonothrombolysis as adjunctive treatment in ST-elevation myocardial infarction (STEMI) patients to reduce infarct size (IS) and preserve left ventricular (LV) function. This study aims to assess infarct characteristics and LV function in STEMI patients treated with sonothrombolysis following primary percutaneous coronary intervention (PCI) on cardiovascular magnetic resonance (CMR) imaging..</div></div><div><h3>Methods</h3><div>Fifty-two STEMI patients were prospectively randomized to receive sonothrombolysis immediately following PCI and underwent early (within seven days after STEMI) and follow-up (6–8 weeks) CMR imaging. IS and distribution pattern, microvascular obstruction, intramyocardial hemorrhage and T1/T2-mapping of infarct and remote zone, as well as LV global longitudinal strain (GLS) and LV ejection fraction (LVEF) were assessed on early CMR. IS and LV systolic function were also assessed on follow-up CMR.</div></div><div><h3>Results</h3><div>Mean age was 58 years, and culprit artery was predominately left anterior descending artery in both groups (92 % and 93 %, respectively). Although there were no differences in IS at baseline and follow-up, infarct pattern was significantly different between the groups on early CMR (patchy LGE pattern in 46 % of the sonothrombolysis vs. 19 % control group, p = 0.04). Significant LVEF improvement (ΔLVEF:7.2 ± 5.4 %, p &lt; 0.01 vs ΔLVEF: 0.9 ± 7.2 %, p = 0.29) and GLS improvement (|ΔGLS|: 3.2 ± 3.2 %, p &lt; 0.01 vs. |ΔGLS|:1.5 ± 4.2 %, p = 0.07) was observed in the sonothrombolysis group, but not in the control group.</div></div><div><h3>Conclusion</h3><div>LV systolic function improvement at 6–8 weeks following STEMI was observed in patients treated with post-PCI sonothrombolysis independent of IS reduction. Further investigation into the effects of post-PCI sonothrombolysis on infarct zone viability is needed.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101757"},"PeriodicalIF":2.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of high-density lipoprotein in infective endocarditis patients after valve surgery","authors":"Shuanglei Zhao ,&nbsp;Qianxian Li ,&nbsp;Zhou Liu ,&nbsp;Bin Wang ,&nbsp;Zhaoqing Sun ,&nbsp;Mingxiu Wen ,&nbsp;Yifan Lu ,&nbsp;Yi Hu ,&nbsp;Siji Chen ,&nbsp;Jie Han ,&nbsp;Hongjia Zhang ,&nbsp;Ming Gong","doi":"10.1016/j.ijcha.2025.101755","DOIUrl":"10.1016/j.ijcha.2025.101755","url":null,"abstract":"<div><h3>INTRODUCTION</h3><div>Lipoproteins and insulin resistance are associated with the prognosis of cardiovascular disease, with strong evidence supporting a causal relationship for some; however, whether lipoproteins and insulin resistance have prognostic value in patients with infective endocarditis after valve surgery remains unclear.</div></div><div><h3>METHODS</h3><div>We included 278 consecutive patients with a definite diagnosis of IE who underwent valve surgery from January 2010 to December 2022. Mortality was analyzed in relation to lipid profile and insulin resistance. Patients were divided into a higher high-density lipoprotein (＞0.905 mmol/L) group and a lower high-density lipoprotein (≤0.905 mmol/L) group based on the cutoff value of the high-density lipoprotein. A Kaplan–Meier survival analysis was conducted for patients in two groups. Subgroup analysis and restricted cubic splines regression of the association between baseline high-density lipoprotein and incident all-cause mortality were performed.</div></div><div><h3>RESULTS</h3><div>Among 278 patients (mean age 44.96 years, 28.1 % female), there were 36 all-cause mortalities during a median 60.98 months follow-up. Kaplan–Meier survival analysis showed lower 12-year mortality in patients with high-density lipoprotein levels &gt; 0.905 mmol/L (HR = 0.125, p &lt; 0.001). There were no significant interactions in any of the subgroups. The adverse effect of high-density lipoprotein on all-cause mortality was consistent after adjusting for the confounders across all subgroups. The restricted cubic splines regression model revealed a linear association between high-density lipoprotein and the risk of all-cause mortality (<em>p</em> for nonlinearity = 0.477), and this linear association is more pronounced in women.</div></div><div><h3>CONCLUSION</h3><div>High-density lipoprotein levels are associated with lower mortality in infective endocarditis patients after valve surgery, particularly in female patients.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101755"},"PeriodicalIF":2.5,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of combining a thiazide diuretic with a loop diuretic in decompensated heart failure: A systematic review and meta-analysis","authors":"Rodrigo Bessa ,&nbsp;Otavio C. Martins ,&nbsp;Isadora Mamede ,&nbsp;Anne E.O. Franchini ,&nbsp;Marcel C.F. Santos","doi":"10.1016/j.ijcha.2025.101739","DOIUrl":"10.1016/j.ijcha.2025.101739","url":null,"abstract":"<div><h3>Background</h3><div>Acute decompensated heart failure (ADHF) often presents as congestion, typically treated with intravenous loop diuretics. However, prolonged use of this therapy may lead to resistance which can be overcome by adding a thiazide diuretic. Less is known about the safety of this combination.</div></div><div><h3>Objectives</h3><div>We aimed to perform a <em>meta</em>-analysis comparing the efficacy and safety of a loop monotherapy versus a combination of loop and thiazide.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) and observational studies comparing patients with ADHF using only loop diuretics to those using a thiazide adjuvant therapy. Statistical analyses were conducted using R software (v 4.3.2) and a random-effects model was employed for all outcomes.</div></div><div><h3>Results</h3><div>Four RCTs and six observational studies, with a total of 17,325 patients, met our inclusion criteria. There was no significant difference in all-cause mortality (RR 1.77; <em>p</em> = 0.094) between the groups. Overall, individuals receiving the diuretic combination experienced greater weight loss (Mean Difference −0.58; <em>p</em> = 0.028) but also had a higher incidence of hyponatremia (RR 2.15; <em>p</em> &lt; 0.001) and hypokalemia (RR 2.27; <em>p</em> &lt; 0.001). There was no significant difference in all hospital readmissions, length of hospital stay, diuresis, and creatinine change.</div></div><div><h3>Conclusions</h3><div>Despite the observed weight loss, combined therapy did not lead to reduction in mortality, hospitalization duration, or hospital readmission, and also increased risk of hyponatremia and hypokalemia. Routine use of combined therapy is not advisable, given the substantial evidence of associated risks outweighing potential benefits.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"59 ","pages":"Article 101739"},"PeriodicalIF":2.5,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial fibroblast activation imaging in prediction of cardiac functional improvement of non-ischemic heart failure","authors":"Yao Su ,&nbsp;Xin Liu ,&nbsp;Ning Fu ,&nbsp;Lina Dou ,&nbsp;Qili Zhang ,&nbsp;Jinxia Zhao ,&nbsp;Qi Yang ,&nbsp;Cunzhi Lu ,&nbsp;Min-Fu Yang","doi":"10.1016/j.ijcha.2025.101752","DOIUrl":"10.1016/j.ijcha.2025.101752","url":null,"abstract":"<div><h3>Background</h3><div>Activated myocardial fibroblasts are key contributors to cardiac fibrosis and drive progression toward heart failure (HF). This study aimed to investigate the characteristics of myocardial fibroblast activation imaging and its predictive value for improved cardiac function in non-ischemic HF.</div></div><div><h3>Methods</h3><div>This double-center prospective study enrolled 38 patients who underwent ^99mTc-labeled-hydrazinonicotinamide-fibroblast activation protein inhibitor-04 (^99mTc-HFAPi) and cardiac magnetic resonance (CMR) imaging. For comparison, 18 healthy volunteers were recruited to undergo ^99mTc-HFAPi imaging as controls, while another 18 controls were selected from the CMR database. Myocardial ^99mTc-HFAPi activity was quantified by intensity, extent, and amount. CMR-derived T1 values, extracellular volume (ECV), and strain were analyzed. Baseline and follow-up echocardiographic data were used to evaluate improved cardiac function.</div></div><div><h3>Results</h3><div>All patients exhibited intense but inhomogeneous ^99mTc-HFAPi uptake in the left ventricular (LV) myocardium, and the intensity was higher than that of controls (4.1 ± 1.8 vs. 1.2 ± 0.1, <em>p</em> &lt; 0.001). LV ^99mTc-HFAPi amount negatively correlated with LVEF (r = -0.43, <em>p</em> = 0.008). At the segmental level, abnormal ^99mTc-HFAPi uptake was present in 79.8 % of segments, exceeding the prevalence of increased native T1 values (66.1 %) (p &lt; 0.001). At median follow-up of 3 months, patients without improved cardiac function demonstrated significantly higher intensity (5.0 ± 2.0 vs. 3.5 ± 1.6, <em>p</em> = 0.022).</div></div><div><h3>Conclusion</h3><div>Patients with non-ischemic HF showed intense but heterogeneous ^99mTc-HFAPi activity. The ^99mTc-HFAPi activity was negatively correlated with baseline cardiac systolic function and associated with poor improvement in cardiac function during follow-up.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101752"},"PeriodicalIF":2.5,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study","authors":"Bárbara Lobato-Delgado ,&nbsp;Magdalena Ruiz ,&nbsp;Carme Font ,&nbsp;Vanessa Pachón ,&nbsp;Victoria Castellón ,&nbsp;Virginia Martínez-Marín ,&nbsp;Mercedes Salgado ,&nbsp;Eva Martínez ,&nbsp;Julia Calzas ,&nbsp;Laura Ortega ,&nbsp;Ana Rupérez ,&nbsp;Oriol Pujol ,&nbsp;José Manuel Soria ,&nbsp;Andrés Muñoz","doi":"10.1016/j.ijcha.2025.101754","DOIUrl":"10.1016/j.ijcha.2025.101754","url":null,"abstract":"<div><div>Cancer patients are at increased risk of venous thromboembolism (VTE), representing one of the main causes of death. In this paper, we used the ONCOTHROMB12-01 study cohort for the analysis of 18-month overall survival (OS) and cancer-associated venous thrombosis (CAT) cumulative incidence. The OS is described for patients with and without CAT across age, sex, cancer type, stage and presence of recurrent VTE using the Kaplan-Meier method and log-rank test. Moreover, a Cox regression model with stepwise feature selection is trained to identify predictors of prognosis. Results show an 18-month CAT cumulative incidence of 16.5 % (CI 13.1–21.0 %) and a median OS for patients with CAT of 9.1 months (CI 5.9–12.5). Furthermore, CAT is associated with shorter survival in lung, colorectal and pancreatic cancer in advanced stages, regardless of age and sex; VTE recurrence also reduces survival significantly. The model found ECOG performance status of 2, cancer type, metastatic stage, VTE, mucinous histology and complete tumor resection as meaningful predictors; the latter being the only protective factor. In conclusion, the diagnosis of CAT has a profound impact on OS in the ONCOTHROMB12-01 study regardless of the clinical characteristics of patients.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101754"},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of late left ventricular thrombus formation after ST-elevation myocardial infarction: A cardiovascular magnetic resonance study","authors":"Magdalena Holzknecht ,&nbsp;Christina Tiller ,&nbsp;Ivan Lechner ,&nbsp;Fritz Oberhollenzer ,&nbsp;Alex Kaser ,&nbsp;Martin Reindl ,&nbsp;Felix Troger ,&nbsp;Mathias Pamminger ,&nbsp;Axel Bauer ,&nbsp;Bernhard Metzler ,&nbsp;Sebastian Johannes Reinstadler ,&nbsp;Agnes Mayr","doi":"10.1016/j.ijcha.2025.101753","DOIUrl":"10.1016/j.ijcha.2025.101753","url":null,"abstract":"<div><h3>Background</h3><div>Little is known about the prevalence of late left ventricular thrombus (LVT) formation after ST-elevation myocardial infarction (STEMI). Compared with transthoracic echocardiography (TTE), cardiovascular magnetic resonance (CMR) imaging has a much higher sensitivity for LVT detection in patients after acute STEMI. However, routine CMR imaging is currently not integrated in post-STEMI management. We sought to develop a practical risk score for the prediction of late LVT formation after STEMI.</div></div><div><h3>Methods and Results</h3><div>Six hundred and nine patients with STEMI underwent CMR at 3 [IQR:2–4] days and 4.4 [IQR:4.1–4.9] months after primary percutaneous coronary intervention (PCI) for acute STEMI. A LVT was visualized in 37 patients (6.1 %) at baseline CMR and was newly diagnosed in 10 patients (1.6 %) at 4 months follow-up (4FU) CMR and in 4 patients (0.7 %, 60 % false-negative rate of TTE in detecting LVT) by 4FU TTE. A simple clinical risk score including associates of late LVT (left anterior descending artery as culprit vessel and 4FU NT-pro-BNP &gt; 236 ng/l), with a range of 0 to 2 points (median risk score: 1 point) showed a strong and significantly higher area under the curve (0.89, 95 %CI 0.86–0.91; p &lt; 0.001) for LVT prediction at 4FU than each individual risk factor alone (p &lt; 0.001). The sensitivity and specificity of the risk score were 100 % and 77 %, respectively.</div></div><div><h3>Conclusions</h3><div>The proposed risk score may offer preliminary utility in predicting late LVT and could help to identify patients with STEMI in whom CMR for late LVT assessment might be particularly informative. Additional investigation in larger cohorts is warranted to validate the clinical application of the score.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101753"},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical burden and management gaps in atherosclerotic cardiovascular disease: A nationwide study of 687,212 patients in Taiwan, 2017–2023","authors":"Fei-Yuan Hsiao ,&nbsp;Yi-Heng Li ,&nbsp;Hsi-Yu Lai ,&nbsp;Lin-Chieh Meng ,&nbsp;Hui-Min Chuang ,&nbsp;Ho-Min Chen ,&nbsp;Chung-Liang Shih ,&nbsp;Wen-Jone Chen","doi":"10.1016/j.ijcha.2025.101749","DOIUrl":"10.1016/j.ijcha.2025.101749","url":null,"abstract":"<div><h3>Objective</h3><div>This nationwide study aimed to analyze temporal trends in hospitalized atherosclerotic cardiovascular disease (ASCVD) incidence, evaluate lipid testing patterns and goal attainment rates, and assess healthcare utilization among ASCVD patients in Taiwan.</div></div><div><h3>Methods</h3><div>Using Taiwan’s National Health Insurance database linked with laboratory data (2017–2023), we identified patients with incident hospitalized ASCVD. We calculated age-standardized incidence rates and analyzed lipid-lowering therapy patterns, low-density lipoprotein cholesterol (LDL-C) testing, and healthcare utilizations during index hospitalization and one-year follow-up.</div></div><div><h3>Results</h3><div>Among 687,212 patients with incident ASCVD, age-standardized incidence decreased by 10% (from 256.3 to 231.8 per 100,000 person-years) from 2017 to 2023, with marked sex disparities (male-to-female ratio: 1.73). Concerning increases in incidence were observed among adults aged 20–29 (12.6%) and 70–79 (19.0%). Among all subtypes of ASCVD, ischemic heart disease (IHD) showed the highest adjusted incidence (99.86 per 100,000 person-years). LDL-C testing rates were suboptimal during index hospitalization (64.8%), with significant variation across ASCVD subtypes (highest in stroke: 80.2% and lowest in peripheral artery disease: 39.2%). Only 34.1% achieved LDL-C &lt;70 mg/dL at one year post-discharge. Lipid-lowering therapy initiation was low during hospitalization (48.9%), peaked at 3 months (60.9%), then stabilized at 57%. Within one year post-discharge, 40.8% had emergency department visits, 40.6% were rehospitalized, and one-year mortality rate reached 13.2%.</div></div><div><h3>Conclusion</h3><div>Our findings reveal substantial gaps in ASCVD care and lipid management in Taiwan’s healthcare system, highlighting critical opportunities for improving preventive strategies and optimizing cardiovascular outcomes in this high-risk population.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101749"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144633912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the storm: rethinking recovery in fulminant myocarditis","authors":"Massimo Imazio","doi":"10.1016/j.ijcha.2025.101750","DOIUrl":"10.1016/j.ijcha.2025.101750","url":null,"abstract":"","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"60 ","pages":"Article 101750"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}